Abstract:Introduction: Rapid advancements in Next Generation Sequencing (NGS) and bioinformatics tools have allowed physicians to obtain genetic testing results in a more rapid, cost-effective, and comprehensive manner than ever before. Around 50% of pediatric sensorineural hearing loss (SNHL) cases are due to a genetic etiology, thus physicians regularly utilize targeted sequencing panels that identify variants in genes related to SNHL. These panels allow for early detection of pathogenic variants which allows physicians to provide anticipatory guidance to families. Molecular testing does not always reveal a clear etiology due to the presence of multigenic variants with varying classifications, including the presence of Variants of Uncertain Significance (VUS). This study aims to perform a preliminary bioinformatics characterization of patients with variants associated with Type II Usher Syndrome in the presence of other multigenic variants. We also provide an interpretation algorithm for physicians reviewing molecular results with medical geneticists. Methods: Review of records for multigenic and/or VUS results identified several potential subjects of interest. For the purposes of this study, two ADGRV1 compound heterozygotes met inclusion criteria. Sequencing, data processing, and variant calling (the process by which variants are identified from sequence data) was performed at Invitae (San Francisco CA). The preliminary analysis followed the recommendations outlined by the American College of Medical Genetics and Association for Molecular Pathology (ACMG-AMP) in 2015 and 2019. The present study utilizes computational analysis, predictive data, and population data as well as clinical information from chart review and publicly available information in the ClinVar database. Results: Two subjects were identified as compound heterozygotes for variants in the gene ADGRV1 . Subject 1's variants were predicted as deleterious, while Subject 2's variants were predicted as non-deleterious. These results were based on known information of the variants from ClinVar, multiple lines of computational data, population databases, as well as the clinical presentation. Discussion: Early molecular diagnosis through NGS is ideal, as families are then able to access a wide range of resources that will ultimately support the child as their condition progresses. We recommend that physicians build strong relationships with medical geneticists and carefully review their interpretation before making recommendations to families, particularly when addressing the VUS. Reclassification efforts of VUS are supported by studies like ours that provide evidence of pathogenic or benign effects of variants.

Gene editing and cardiac disease modelling for the interpretation of genetic variants of uncertain significance in congenital heart disease

A Screening Approach to Identify Clinically Actionable Variants Causing Congenital Heart Disease in Exome Data

Molecular convergence of risk variants for congenital heart defects leveraging a regulatory map of the human fetal heart

Extensive Identification of Genes Involved in Congenital and Structural Heart Disorders and Cardiomyopathy

CRISPR single base editing, neuronal disease modelling and functional genomics for genetic variant analysis: pipeline validation using Kleefstra syndrome EHMT1 haploinsufficiency

Integrative analysis of genomic variants reveals new associations of candidate haploinsufficient genes with congenital heart disease

Computational analysis of congenital heart disease associated SNPs: Unveiling their impact on the gene regulatory system

Deciphering pathogenicity of variants of uncertain significance with CRISPR-edited iPSCs

Identification Of Novel Single-Nucleotide Variants With Potential Of Mediating Malfunction Of Microrna In Congenital Heart Disease

Basic science methods for the characterization of variants of uncertain significance in hypertrophic cardiomyopathy

Multiple gene variations contributed to congenital heart disease via GATA family transcriptional regulation

Abstract 11332: Integration of Protein Interactome Networks with Congenital Heart Disease Variants Reveals Candidate Disease Genes

Cardiovascular Disease Pathogenicity Predictor (CVD-PP): A Tissue-Specific In Silico Tool for Discriminating Pathogenicity of Variants of Unknown Significance in Cardiovascular Disease Genes

Functional dissection of human cardiac enhancers and noncoding de novo variants in congenital heart disease

The New Challenge in Congenital Heart Disease

Identification of Long Non-coding RNA Candidate Disease Genes Associated with Clinically Reported CNVs in Congenital Heart Disease

Whole genome sequencing of families diagnosed with cardiac channelopathies reveals structural variants missed by whole exome sequencing

Transcription factor protein interactomes reveal genetic determinants in heart disease

Saturation genome editing maps the functional spectrum of pathogenic VHL alleles

Bioinformatics characterization of variants of uncertain significance in pediatric sensorineural hearing loss

Regional Variation in Cardiovascular Genes Enables a Tractable Genome Editing Strategy